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Abstract
Purpose To investigate the long-term safety (primary endpoint) and effectiveness (secondary endpoint) of the somatropin 
biosimilar  Omnitrope®.
Methods PATRO Children is an ongoing, multicenter, observational, post-marketing surveillance study. Children who 
received  Omnitrope® for any indication were included. Adverse events (AEs) were evaluated in all study participants. Auxo-
logical data, including height standard deviation scores (HSDS) and height velocity standard deviation scores (HVSDS), were 
used to assess effectiveness. In this snapshot analysis, data from the Italian subpopulation up to August 2017 were reported.
Results A total of 291 patients (mean age 10.0 years, 56.0% male) were enrolled at 19 sites in Italy. The mean duration of 
 Omnitrope® treatment was 33.1 ± 21.7 months. There were 48 AEs with a suspected relationship to the study drug (as reported 
by the investigator) that occurred in 35 (12.0%) patients, most commonly headache, pyrexia, arthralgia, insulin-like growth 
factor above normal range, abdominal pain, pain in extremity and acute gastroenteritis. There were no confirmed cases of 
type 1 or type 2 diabetes; however, two patients (0.7%) had impaired glucose tolerance that was considered  Omnitrope® 
related. The mean HSDS increased from − 2.41 ± 0.73 at baseline (n = 238) to − 0.91 ± 0.68 at 6.5 years (n = 10). The mean 
HVSDS increased from − 1.77 ± 1.38 at baseline (n = 136) to 0.96 ± 1.13 at 6.5 years (n = 10).
Conclusions In this sub-analysis of PATRO Children,  Omnitrope® appeared to have acceptable safety and effectiveness in 
the treatment of in Italian children, which was consistent with the earlier findings from controlled clinical trials.
Keywords Adolescents · Children · Infants · Omnitrope® · Pediatric · Recombinant human growth hormone
Background
Recombinant human growth hormones (rhGH) have been 
established as safe and effective for the treatment of various 
growth disorders in children, with several rhGH products 
now licensed [1–3].
Omnitrope® (Sandoz GmbH, Kundl, Austria) is a soma-
tropin developed as the biosimilar medicinal product to the 
originator  Genotropin® (Pfizer Limited, Sandwich, UK). In 
2006,  Omnitrope® was the first product to be approved by 
the European Medicines Agency (EMA) via the European 
regulatory pathway for biosimilars.  Omnitrope® is licensed 
for use in treating infants, children, and adolescents with 
growth hormone deficiency (GHD), those born small for 
gestational age (SGA) and those with conditions that can 
affect growth such as Turner syndrome (TS), chronic renal 
insufficiency (CRI) and Prader–Willi syndrome (PWS) [4]. 
 Omnitrope® is also approved for the treatment of patients 
with idiopathic short stature (ISS) in the USA, Canada, and 
Brazil. Pivotal phase III clinical trials demonstrated that 
 Omnitrope® is safe and efficacious for the treatment of GHD 
in infants, children, and adolescents [5, 6].
The PAtients TReated with  Omnitrope® (PATRO) Chil-
dren post-marketing surveillance study was initiated to com-
plement the phase III clinical trial data as part of an EMA 
post-approval Risk Management Plan. The PATRO Chil-
dren is an ongoing international, multicenter, longitudinal, 
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non-interventional study that is investigating the long-term 
safety and efficacy of  Omnitrope® in children with growth 
disturbances [7]. As of August 2017, 5797 patients have 
been recruited from 297 sites across 14 different countries 
(Austria, Canada, Czech Republic, France, Germany, Italy, 
Poland, Romania, Slovenia, Spain, Sweden, Taiwan, UK, 
USA) to participate in the study.
Interim 1-year results of all patients recruited up to Sep-
tember 2012 (n = 1837) have previously been reported [7], 
with annual updates presented at international meetings [8, 
9]. In addition, a snapshot analysis of patients enrolled at 
Italian sites since the beginning of the study up to August 
2015 has previously been published [10]. Herein we report 
the results of a second snapshot analysis of patients (n = 291) 




The design of the PATRO Children study has been pre-
viously published in detail [7]. Briefly, PATRO Children 
was a multicenter, open-label, longitudinal post-market-
ing surveillance study conducted at 297 children’s hospi-
tals and specialist endocrinology clinics in 15 countries 
where  Omnitrope® is available. Nineteen centers in Italy 
participated. Patients eligible for PATRO Children were 
infants, children, and adolescents receiving treatment with 
 Omnitrope® for any diagnosis. Both hormone treatment-
naïve patients and patients who had previously been treated 
with another rhGH product before starting  Omnitrope® were 
eligible for inclusion. All patients were required to provide 
written informed consent (or have consent provided by a par-
ent or legal guardian). The study was reviewed and approved 
by each study site’s Independent Ethics Committee/Institu-
tional Review Board, and was conducted in accordance with 
the Oviedo Human Rights Convention and the Declaration 
of Helsinki.
Treatment and outcomes
Patients participating in the PATRO Children study received 
 Omnitrope® treatment in accordance with the recommenda-
tions in the European Medicines Agency Summary of Prod-
uct Characteristics [4] and/or the prescribing information of 
the respective countries.
The primary objective of the study was to assess the 
long-term safety of  Omnitrope® in infants, children, and 
adolescents treated in routine clinical practice, including in 
patients with PWS. All adverse events (AEs) and serious 
AEs (SAEs) were recorded irrespective of causality. AEs of 
special interest were the development of diabetes or malig-
nancies. The development and clinical implications of anti-
bodies to rhGH were also investigated.
A secondary objective of the study was to assess the long-
term effectiveness of  Omnitrope® treatment. Height meas-
urements were used to determine height standard deviation 
scores (HSDS) and height velocity standard deviation scores 
(HVSDS) [11, 12].
Data collection and verification
Data were collected at each routine visit during treatment 
with  Omnitrope®, with the frequency of visits determined at 
the discretion of the treating physician. No additional visits 
were scheduled as part of the protocol. Patient data were 
recorded and entered into an electronic case report form 
(eCRF) at least once a year during the study, along with 
any other available clinical information (e.g., findings from 
examinations [pubertal stage, bone age, vital signs, body 
composition, and body mass index (BMI)], concomitant 
medications, AEs). Laboratory tests performed at baseline 
were hematology, blood chemistry, glucose metabolism 
parameters [including oral glucose tolerance test (OGTT)], 
fasting lipid profile, urinalysis, hormones (thyroid, gonadal 
and adrenal), levels of insulin-like growth factor 3 (IGF-3) 
and insulin-like growth factor-binding protein 3 (IGFBP-3), 
and anti-rHGH antibodies. Laboratory tests conducted at 
subsequent visits were those performed as part of routine 
clinical practice.
All eCRFs were entered into a centralized web-based 
electronic data collection system, and were monitored by a 
contract research organization (CRO). The system includes 
automatic plausibility checks such that any entered data 
point that is outside the expected range generates an auto-
matic query. Complete data cleaning will be performed by 
the CRO on completion of the study.
Statistical analysis
Statistical calculations in this analysis were performed using 
the software package SAS version 9.3 as described previ-
ously [10]. The statistical parameters calculated for continu-
ous/quantitative variables were descriptive and included the 
number of data values available, the number of data values 
missing, arithmetic mean, standard deviation, minimum, 
median, and maximum. The incidence of AEs was calcu-
lated per patient-year, where a patient-year was defined as 
the total sum of the number of years that each child has 
been under observation in this study and calculated as fol-
lows: (date of last documented visit − baseline date)/365.25. 
Because this post-marketing surveillance is ongoing, any 
data used in this snapshot analysis were not fully cleaned, 
Journal of Endocrinological Investigation 
1 3
although data quality was checked by plausibility checks and 
online queries on an ongoing basis.
Results
The majority (95.5%) of patients in this analysis were naïve 
to hormone therapy at enrolment, with  Omnitrope® pre-
scribed as their first therapy. As of August 2017, 291 patients 
(mean age 10.0 years, 56.0% male) had been enrolled at 
19 sites in Italy (Table 1) and had received  Omnitrope® 
treatment for a mean duration of 33.1 ± 21.7  months 
(2.8 ± 1.8 years). Mean age at diagnosis was 9.4 ± 3.5 years 
and mean age at the start of treatment was 10.0 ± 3.3 years.
Treatment was discontinued in 140 of the 291 patients 
(48.1%) at the time of the analysis. Reasons for discontin-
uation listed in the eCRFs included patient reached final 
height/bone age maturation (n = 46; 32.9% of patients); 
switch to other growth hormone product (n = 21; 15.0%); 
lost to follow-up (n = 19; 13.6%); reached near final height 
(n = 7; 5.0%); non-responder (n = 4; 2.9%); AE (n = 3; 
2.1%); patient non-compliance (n = 2; 1.4%); a slowdown 
of height velocity (patients grew < 1 cm/year; n = 1; 0.7%); 
patient satisfied with height (n = 1; 0.7%); patient did not 
wish to continue the injections (n = 1; 0.7%); referral to adult 
endocrinologist (n = 1; 0.7%); other reason (n = 34; 24.3%). 
Among the patients who discontinued because of AEs, only 
one event was considered related to  Omnitrope® (described 
below).
Safety
Up until August 2017, 344 AEs occurred in 138 (47.4%) 
of the 291 patients in the Italian safety analysis set over a 
mean treatment duration of 33.1 ± 21.7 months. There were 
48 AEs with a suspected relationship to the study drug (as 
reported by the investigators), occurring in 35 (12.0%) 
patients. Of these, 43 AEs (n = 31; 10.7%) were mild and 
5 AEs (n = 4; 1.4%) were moderate in intensity. Complete 
resolution was reported for 34 AEs (n = 25; 8.6%), while 1 
AE [obstructive apnea (n = 1); 0.3%] resolved with sequelae 
after treatment interruption and 13 AEs (n = 12; 4.1%) were 
ongoing at the time of analysis. As a result of drug-related 
AEs, the dose of  Omnitrope® was increased in two patients 
(0.7%), one who had received a lower-than-prescribed dose 
and one with hyperinsulinism, and reduced in six patients 
(2.1%), four with elevated levels of insulin-like growth fac-
tor-1 (IGF-1), one with hyperglycemia, and one with both 
elevated IGF-1 and insulin resistance. All but one of these 
AEs had resolved completely by the time of reporting; one 
14-year-old girl had ongoing high IGF-1 (in the 97th per-
centile for age and sex).  Omnitrope® treatment was inter-
rupted due to AEs in nine patients (3.1%) and permanently 
discontinued in one patient (0.3%). Reasons for treatment 
interruption were elevated levels of IGF-1 (n = 3), headache 
(n = 1), gait disorder (n = 1), minimal regrowth of a crani-
opharyngioma (n = 1), abnormal glucose (n = 1), asthenia 
(n = 1), and obstructive apnea (n = 1). All but the latter 
resolved completely after treatment interruption. The patient 
who permanently discontinued  Omnitrope® was an 11-year-
old female with TS who developed an elevated IGF-1 level 
Table 1  Baseline characteristics and demographics of patients 
enrolled at sites in Italy in the PATRO Children study as of August 
2017
All values are presented as mean ± standard deviation unless other-
wise stated
BMI body mass index, HSDS Height Standard Deviation Scores, 
Nmiss number of patients with data missing




Chronological age at the start of treat-
ment, years
10.0 ± 3.25
Pubertal status, n (%)
 Prepubertal 225 (77.3)
 Pubertal 66 (22.7)
HSDS − 2.40 ± 0.74 (Nmiss = 35)
Height velocity, cm/year 3.6 ± 1.6 (Nmiss = 143)
BMI, kg/m2 16.8 ± 3.2 (Nmiss = 40)
Age at diagnosis, years 9.4 ± 3.5
Diagnosis at presentation, n (%)





 Small for gestational age 18 (6.2)
 Prader–Willi syndrome 7 (2.4)
 Idiopathic short stature 7 (2.4)
 Turner Syndrome 3 (1.0)
 Chronic renal insufficiency 1 (0.3)
 Other 10 (3.4)






Previous treatment status, n (%)
 Treatment-naïve 278 (95.5)
 Pre-treated 13 (4.5)
Omnitrope® dosing at baseline, mg/kg/day 0.031 ± 0.005
(Nmiss = 95)
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(722.5 ng/mL) after 4.25 years of treatment. The elevated 
IGF-1 level resolved after treatment discontinuation.
The most common AEs reported (incidence > 10 over 
822.0 patient-years) were headache (25 patients; 8.6%), 
pyrexia (13 patients; 4.5%), arthralgia (11 patients; 3.8%), 
IGF-1 level above normal range (10 patients; 3.4%), abdomi-
nal pain (9 patients; 3.1%), pain in extremity (9 patients; 
3.1%) and acute gastroenteritis (9 patients; 3.1%) (Table 2). 
Of the ten patients who had higher than normal levels of 
IGF-1, only one had another AE (headache).
Headache was reported as an AE 31 times in 25 patients 
(16 females and 9 males). All headaches were either mild (26 
headaches) or moderate (5 headaches) in severity. Only three 
headaches (two mild and one moderate) were suspected to 
be related to  Omnitrope®. Two patients with headache had 
 Omnitrope® interrupted, but in only one of these cases (a 
moderate headache) was  Omnitrope® suspected to be the 
cause of the headache. In all other patients,  Omnitrope® was 
continued without change.
A total of 35 SAEs were reported in 21 (7.2%) patients. 
Among these, two SAEs in two patients were suspected of 
being related to  Omnitrope® treatment, and included one 
patient with gait disturbance and a worsening of walking 
difficulties and one patient with a minimal increase in a 
known residual craniopharyngioma [10]. However, it is 
possible that the regrowth of the craniopharyngioma was 
spontaneous and unrelated to treatment since a high propor-
tion (3–50%) of craniopharyngiomas recur some time after 
partial removal. The patient with craniopharyngioma was a 
19-year-old male who had been receiving  Omnitrope® treat-
ment at 0.005 mg/kg/day for 5 months.  Omnitrope® treat-
ment was interrupted for safety reasons and then restarted 
4 months later; there was no increase in the size of the crani-
opharyngioma after restarting  Omnitrope®. The patient with 
gait difficulties was an 8-year-old boy with isolated GHD 
and a history of psychomotor delay, epilepsy, and hypothy-
roidism. After 5 months of treatment with  Omnitrope® (dose 
0.032 mg/kg/day), his walking difficulties worsened. Treat-
ment was interrupted and the gait disturbance resolved, but 
investigators considered that it was not possible to assess the 
relationship with  Omnitrope®. Both of these SAEs devel-
oped within the first 2 years of  Omnitrope® treatment, and 
have been reported previously [10]. No new SAEs were 
reported and the incidence of each of these SAEs was 1.2 
per 1000 patient-years.
To date, there have been no confirmed cases of type 1 or 
type 2 diabetes with  Omnitrope® treatment among patients 
in the Italian safety analysis set although risk factors for 
diabetes have been reported as drug-related AEs (Table 2); 
in this analysis, one case of hyperglycemia suspected of 
being drug related was reported. In addition, two patients 
(0.7%) had impaired glucose tolerance; BMI information 
was available for one of them (aged 13.4 years) and was 
24.97 kg/m2 (1.67 SDS, 97th percentile according to World 
Health Organization charts). Both patients had isolated 
GHD of unknown etiology and were treatment naïve. In both 
patients, impaired glucose tolerance was considered related 
to  Omnitrope®. Impaired glucose tolerance did not lead to 
changes in  Omnitrope® treatment and patients received treat-
ment for 37 and 45 months, respectively, before discontinu-
ing because the center closed or they had reached their final 
height/bone age.
Scoliosis was reported in three patients (1.0%, 3.65 per 
1000 patient-years), all of whom were treatment naïve at the 
time of starting  Omnitrope®. Mild scoliosis was reported in 
one patient with GHD 7–12 months after the start of GH 
therapy and in one patient with ISS during the fourth year of 
GH therapy. Moderate scoliosis was reported in one patient 
with PWS during the second year of GH therapy. In the 
patient with ISS, scoliosis was considered serious. Scoliosis 
was not considered to be related to  Omnitrope® in any of 
these patients.
Efficacy
Omnitrope® treatment was associated with increases 
in both HSDS and HVSDS; this was consistent with 
Table 2  Most common drug-
related AEs and AEs of interest 
in the Italian safety analysis set 
(n = 291)
a Preferred term/MedDRA dictionary
b Until cut-off date
Adverse  eventsa Patients, n (%) Incidence 
(patient-
yearsb = 822.0)
Insulin-like growth factor above normal range 10 (3.4) 12.17
Insulin above normal range 5 (1.7) 6.08
Blood creatine phosphokinase increased 4 (1.4) 4.87
Scoliosis 3 (1.0) 3.65
Impaired glucose tolerance 2 (0.7) 2.43
Headache 2 (0.7) 2.43
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previously reported sub-analyses of the PATRO Children 
study [7, 9, 10].
The mean HSDS increased from a baseline value 
of − 2.41 ± 0.73 (n = 238) to − 1.30 ± 0.94 at 4  years 
(n = 53) and to − 0.91 ± 0.68 at 6.5  years (n = 10) 
(Fig. 1). Mean HVSDS increased from a baseline value 
of − 1.77 ± 1.38 (n = 136) to a peak mean of 2.43 ± 2.31 
at 0.5  years (n = 229) and stabilized to 1.00 ± 1.69 at 
4.0 years (n = 53) and 0.96 ± 1.13 at 6.5 years (n = 10) 
(Fig. 2). HSDS and HVSDS appeared to increase from 
6.5 to 8.5 years of treatment; however, as the number of 
Italian patients over this time was low (< 10 patients), no 
formal analysis was conducted.
Pre-pubertal treatment-naïve patients with GHD 
(from −  2.49 ± 0.73 to −  1.92 ± 0.70) and SGA (from 
− 3.02 ± 0.39 to − 2.54 ± 0.39) had the largest increase in 
HSDS at 12 months compared with the overall population of 
patients who received pre-treatment [from − 1.67 ± 0.83 to 
− 1.36 ± 0.74 (GHD) and from − 2.64 ± 0.27 to − 2.23 ± 0.27 
(SGA), respectively] and the overall population of treatment-
naïve patients [from − 2.43 ± 0.69 to − 1.90 ± 0.68 (GHD) 
and from − 3.02 ± 0.39 to − 2.64 ± 0.46 (SGA); Fig. 3a].
Fig. 1  Change in Height Stand-
ard Deviation Scores (HSDS) in 
the Italian total efficacy analysis 
set (n = 238) over 6.5 years of 
the study duration
Fig. 2  Change in Height 
Velocity Standard Deviation 
Scores (HVSDS) in the Italian 
total efficacy analysis set over 
6.5 years of the study duration
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For treatment-naïve patients, the mean HSDS increased 
from a baseline of − 2.43 ± 0.69 (GHD) and − 3.02 ± 0.39 
(SGA) to −  1.19 ± 0.65 (GHD) and −  1.06 (SGA) in 
5 years (Fig. 3b).
HSDS and HVSDS by indication are presented in 
Fig. 4a, b, respectively. At 3.0 years, patients with TS had 
the highest HSDS and HVSDS; however, no further data 
for patients with this indication are available. At 6.0 years, 
patients with SGA had higher HSDS and HVSDS com-
pared with patients who had GHD [− 0.92 ± 0.59 vs − 0.58 
(SD not available) and 1.09 ± 1.65 vs 2.36 (SD not avail-
able), respectively].
HSDS and HVSDS by sex are presented in Fig. 5a, b, 
respectively. HSDS was lower in males than in females at 
3.0 years (− 1.48 ± 0.97 vs − 1.43 ± 0.68) and 6.0 years 
(− 0.95 ± 0.66 vs − 0.85 ± 0.52), but HVSDS was higher 
in males than in females at 3.0  years (1.19 ± 1.84 vs 
1.11 ± 1.39) and 6.0 years (1.44 ± 1.25 vs 0.94 ± 1.95).
Discussion
The results of this analysis support and extend the findings 
of an earlier sub-analysis in Italian patients in the PATRO 
Children study [10] and provide further evidence that 
 Omnitrope® treatment is effective and well tolerated over the 
longer term, with no new safety concerns becoming appar-
ent during treatment for up to 8.5 years. Of note, no new 
SAEs suspected to be related to  Omnitrope® treatment were 
reported in the 2-year period between the first and second 
snapshot analyses. In addition, the findings in the Italian 
subgroup are generally consistent with those reported for 
Fig. 3  Change in Height Stand-
ard Deviation Scores (HSDS) 
in a Italian patients with growth 
hormone deficiency (GHD) and 
patients that were small for ges-
tational age (SGA) at 12 months 
and b treatment-naïve Italian 
patients with GHD and SGA
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the full (global) study population [7–9]. Similarly, safety 
findings from this sub-analysis were also consistent with 
published data for  Genotropin®, in which the rate of total 
AEs per patient-year was 0.849 [6].
Given concerns about a potential link between rhGH 
treatment and the development of diabetes [13], the PATRO 
Children study objectives included a particular focus on 
investigating the diabetogenic potential of  Omnitrope® [7]. 
Fig. 4  Effectiveness outcomes 
by indication. a Height Standard 
Deviation Scores (HSDS) and b 
height velocity standard devia-
tion scores (HVSDS)
 Journal of Endocrinological Investigation
1 3
There have been no confirmed cases of type 1 or type 2 
diabetes with  Omnitrope® treatment among patients in the 
Italian safety analysis set, and just one adverse drug reac-
tion of diabetes reported to date in the full study population 
(n > 5000) [9].
The investigation of the occurrences of malignancies in 
 Omnitrope®-treated patients was also a key objective of the 
PATRO Children study [7]. The current analysis, together 
with the global data [9], showed no evidence of an increased 
risk of malignancies associated with  Omnitrope® treatment.
Treatment with rhGH may be associated with musculo-
skeletal AEs. In the present study, scoliosis was reported 
in three patients and was considered serious in one. This 
patient had ISS. Scoliosis is reported in approximately 0.2% 
of patients with GHD and occurs as a result of rapid growth 
and not as a direct effect of GH therapy [3]. Gait disturbance 
was reported in one patient in the present study (incidence 
1.2 per 1000 patient-years). This AE was considered serious 
and related to  Omnitrope® therapy. In patients with GHD, 
the incidence of slipped capital femoral epiphysis has been 
reported to be 73 per 100,000 patient-years [3].
The efficacy data of the current analysis support previous 
results showing a positive effect of  Omnitrope® treatment on 
HSDS and HVSDS in pediatric Italian patients with growth 
hormone disorders, confirming outcomes of previous phase 
3 studies [5, 6]. The efficacy of  Omnitrope® was also shown 
to be similar to its reference medicine,  Genotropin®. This 
was consistent with the published literature, which found 
 Omnitrope® and  Genotropin® were bioequivalent in their 
efficacy, pharmacokinetics, and pharmacodynamics [14, 15].
Interestingly, analysis of the Kabi Pharmacia Interna-
tional Growth Study (KIGS) database found that age at 
rhGH treatment start is inversely correlated with the growth 
response [16]. In the present analysis, the mean age of 
patients at baseline was 10.0 ± 3.25 years (10.5 years for 
males, and 9.3 years for females) and patients were generally 
Fig. 5  Effectiveness outcomes 
by sex. a Height Standard 
Deviation Scores (HSDS) and 
b Height Velocity Standard 
Deviation Scores (HVSDS)
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older at enrolment for every indication; in the global study 
population, the mean age was 9.1 years [9]. However, treat-
ment-naïve patients had a mean age (9.5 years) that was 
closer to the age of patients in the global study. Furthermore, 
treatment-naïve patients who initiated treatment before the 
onset of puberty had a greater response in HSDS increase 
for both GHD and SGA indications, compared with older 
treatment-naïve patients. Given the importance of initiating 
rhGH treatment before pubertal onset [16], the potential to 
achieve greater benefit by starting treatment earlier should 
be considered.
As expected, hormone treatment-naïve patients had 
a lower baseline HSDS (−  2.43 ± 0.69 for GHD and 
− 3.02 ± 0.39 for SGA), compared with the total Italian 
population (− 2.41 ± 0.73). However, growth responses fol-
lowed a similar trend for both populations.
There were some differences between the demographic 
and disease characteristics of the patients in the full analysis 
of the PATRO Children study and the present analysis of 
Italian patients. In the global study population, 57.0% of 
enrolled patients had GHD and 45.5% of the patients were 
born SGA [9]. In the present analysis, 84.2% of patients had 
GHD and 6.2% of patients were born SGA. This may be an 
indication of different diagnosis and/or treatment protocols 
in Italian children compared with other countries [10].
While the results of this current analysis are supportive of 
the long-term interventional trials of  Omnitrope®, there are 
some limitations to the interpretation of these findings. As 
mentioned above, the patients included in this analysis were 
predominantly diagnosed as having GHD, and this sample 
is not representative of all the different indications of rhGH 
treatment. Furthermore, the observational study design and 
the interim nature of this analysis can only provide a snap-
shot of treatment in these patients, and ongoing data from 
the study are required to confirm our results. The discontinu-
ation rate in the study was high, as expected for a pediatric 
population who may discontinue rhGH treatment on reach-
ing final height or bone age. The mean age of patients at 
the start of treatment is consistent with these results and 
explains the small number of patients with 6.5 years of con-
tinuous treatment. Finally, the data in this snapshot analysis 
have not been fully cleaned, although we can be confident 
in the quality based on the plausibility checks and online 
queries undertaken regularly throughout the data collection 
process. However, this study retains the advantage of reflect-
ing real-world clinical practice in Italy in this context.
Conclusions
The results from the longitudinal post-marketing surveil-
lance study of  Omnitrope® were consistent with those 
observed in controlled clinical trials. The reported analysis 
supports and extends earlier findings of the PATRO Children 
study and provides further evidence that  Omnitrope® is safe, 
well tolerated, and effective in the treatment of a range of 
pediatric growth disorders.
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